T1	Participants 412 616	patients (n=209 MG, n=96 placebo) with UC in remission [revised Sutherland Disease Activity Index (SDAI) rectal bleeding=0, mucosal appearance <2] who took MG 1.5 g or placebo once-daily for up to 6 month
T2	Participants 889 952	percentage of relapse-free patients at month 6/end of treatment
